Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye. See the future of eye care with Aerie.
Location: United States, North Carolina, Durham
Employees: 501-1000
Total raised: $254M
Founded date: 2005
Investors 3
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | Sofinnova ... | sofinnova.... |
| - | TPG | tpg.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.12.2021 | - | $88M | - |
| 09.09.2014 | - | $125M | - |
| 07.03.2011 | Series B | $41M | - |
Mentions in press and media 6
| Date | Title | Description |
| 18.11.2019 | Aerie Pharmaceuticals announces agreement to acquire Avizorex Pharma, S.L., owned by Inveready | 18/11/2019 Press Release AERIE PHARMACEUTICALS ANNOUNCES AGREEMENT TO ACQUIRE AVIZOREX PHARMA, S.L., OWNED BY INVEREADY. Company Plans to Commence Phase 2b Study in Dry Eye Subjects in Late 2020 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)... |
| 01.10.2014 | Aerie Pharmaceuticals Completes $125M Financing | Newport Beach-based pharmaceuticals developer Aerie Pharmaceuticals said late Tuesday that it has completed its $125M, convertible note financing from Deerfield Management Company. The financing deal had been announced earlier in the month.... |
| 09.09.2014 | Aerie Pharmaceuticals Raises $125M | Newport Beach-based Aerie Pharmaceuticals said today that it has raised $125M in a convertible note financing. The publicly held pharmaceuticals firm--which is developing treatments for glaucoma--said the funding came from a current shareho... |
| 07.03.2011 | Aerie Pharmaceuticals Raises $30M in Series B Financing | Aerie Pharmaceuticals Inc., a Bridgewater, N.J.-based biotechnology company that develops medical innovations in ophthalmology, has closed $30m in Series B financing. The round was co-led by Clarus Ventures and Sofinnova Ventures, with part... |
| 02.03.2011 | Glaucoma treatment pharma company Aerie closes $41M venture round | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recov... |
| - | Glaucoma treatment pharma company Aerie closes $41M venture round | Glaucoma treatment company Aerie Pharmaceuticals has closed a $41.3 million round of financing as the company prepares for late stage clinical trials on its lead drug candidate. The company raised the money quickly; securities filings show ... |